327 related articles for article (PubMed ID: 2851191)
21. Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits.
Ofosu FA; Fernandez F; Anvari N; Caranobe C; Dol F; Cadroy Y; Petitou M; Mardiguian J; Sié P; Boneu B
Thromb Haemost; 1988 Oct; 60(2):188-92. PubMed ID: 2905842
[TBL] [Abstract][Full Text] [Related]
22. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
Cziraky MJ; Spinler SA
Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
[TBL] [Abstract][Full Text] [Related]
23. Low molecular weight heparins--state-of-the-art and unsolved issues.
Breddin HK
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
[TBL] [Abstract][Full Text] [Related]
24. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
25. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
26. From unfractionated heparins to low molecular weight heparins.
Hirsh J
Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
[TBL] [Abstract][Full Text] [Related]
27. Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins.
Nguyên P; Rémy MG; Potron G
Haemostasis; 1999; 29(6):301-9. PubMed ID: 10844403
[TBL] [Abstract][Full Text] [Related]
28. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
Fareed J; Kumar A; Rock A; Walenga JM; Davis P
Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
[TBL] [Abstract][Full Text] [Related]
29. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
Sissi C; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of low molecular weight heparins.
Bara L; Samama M
Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
[TBL] [Abstract][Full Text] [Related]
31. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
Alban S; Welzel D; Hemker HC
Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
[TBL] [Abstract][Full Text] [Related]
33. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
Barrowcliffe TW; Le Shirley Y
Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814
[TBL] [Abstract][Full Text] [Related]
34. Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes.
Cohen M
Semin Hematol; 1999 Jan; 36(1 Suppl 1):33-6. PubMed ID: 9930562
[TBL] [Abstract][Full Text] [Related]
35. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
36. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
[TBL] [Abstract][Full Text] [Related]
37. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
Schoen P; Lindhout T; Hemker HC
Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
[TBL] [Abstract][Full Text] [Related]
38. The mode of action of CY216 and CY222 in plasma.
Béguin S; Wielders S; Lormeau JC; Hemker HC
Thromb Haemost; 1992 Jan; 67(1):33-41. PubMed ID: 1319616
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Bendetowicz AV; Béguin S; Caplain H; Hemker HC
Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
[TBL] [Abstract][Full Text] [Related]
40. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
